Skip to main content
MDXG
NASDAQ Industrial Applications And Services

MiMedx Q2 Call: $350M Sanara Acquisition Financing, Synergies, and Standalone Recovery Detailed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$3.8
Mkt Cap
$630.04M
52W Low
$3.025
52W High
$7.99
52W Position info
26% above low
Off High info
52% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MDXG sits 26% above its 52-week low of $3.025.

Summary

MiMedx's Q2 call detailed the financing and synergy plan behind its $350M Sanara acquisition, projecting a combined company with >$400M revenue and 20%+ EBITDA margins in 2027, while standalone results showed a strong sequential recovery in wound care.


Key Events · M&A and Partnerships · MDXG

  • Acquisition Financing Secured

    MiMedx secured a $300M six-year term loan from Hayfin Capital at SOFR + 6.25% to fund the Sanara acquisition, and initiated prepayment of its existing term loan with Citizens and Bank of America.

  • 2027 Combined Financial Targets

    Post-close, the combined company expects 2027 revenue well in excess of $400M, adjusted EBITDA margin of at least 20%, and rapid de-levering to under 3x adjusted EBITDA by year-end 2027.

  • Cost Synergy Breakdown

    More than half of the expected $20M+ in annual cost synergies will come from G&A, with the remainder spread across other areas, driving immediate accretion.

  • Minimal Share Dilution

    The deal will issue ~4.2M shares, but after prior buybacks of ~3.5M shares at $3.67, the net increase to the float is only about 700,000 shares.


Analysis · MDXG · Industrial Applications And Services

MiMedx's Q2 earnings call provides critical new details on its $350M acquisition of Sanara MedTech, including a $300M term loan at SOFR+6.25%, $20M+ in cost synergies (mostly G&A), and a net share increase of only ~700K after buybacks. The combined company is expected to generate over $400M in 2027 revenue with 20%+ adjusted EBITDA margins, rapidly de-levering. Standalone, MiMedx showed a 9% sequential revenue rebound to $64M, driven by 44% sequential wound care center volume growth, and reiterated its 2026 guidance. This call transforms the acquisition from a headline into a fully financed, synergy-backed plan with a clear path to profitability, making it highly market-moving.

At the time of this filing, MDXG was trading at $3.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $630M. The 52-week trading range was $3.03 to $7.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MDXG - Latest Insights

MDXG
Jul 29, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.15
Real-time Price: $3.80 info
Change: -$0.350 (-8%) info
Market Cap: $630.04M info
MDXG
Jul 29, 2026, 4:07 PM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $4.15
Real-time Price: $3.80 info
Change: -$0.350 (-8%) info
Market Cap: $630.04M info
MDXG
Jul 29, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.15
Real-time Price: $3.80 info
Change: -$0.350 (-8%) info
Market Cap: $630.04M info
MDXG
Jul 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.18
Real-time Price: $3.80 info
Change: -$0.380 (-9%) info
Market Cap: $630.04M info
MDXG
Jul 29, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $3.80 info
Change: -$0.380 (-9%) info
Market Cap: $630.04M info